Health and Healthcare

Targacept: Late Day Volume Surge Deserves Attention

by H.S. Ayoub
BioHealth Investor.com

Shares of Targacept (TRGT) traded heavily, and suddenly, late during Tuesday’s trading. While the stock price popped along with the volume surge, shares ended down 3 pennies at $8.90. The day’s total volume was more than 5x the 3-month daily average.

Targacept engages in the design, discovery, and development of drugs for the treatment of multiple diseases and disorders of the central nervous system. As of December 31, 2006, the company had four clinical-stage product candidates and three preclinical product candidates in its product portfolio.

Targacept’s market cap is a tiny $170 million with more than $54 million in cash holdings, and $1.4 million in debt as last reported by Yahoo!Finance.

I caught the volume surge in time before the end of trading and purchased shares at $9.25. While shares ended regular hours trading at $8.90, a trade of $9.37 was registered after hours at 6:04 pm, again according to Yahoo!.

Shares of Targacept did not make BHI’s BioWatch Alert list however, as a price jump of at least %5 is required before the end of regular hours trading.

But Wednesday’s trading session should prove interesting for Targacept shares. Keep a close eye on this stock tomorrow!

Source: BioHealth Investor.com

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.